FDA panel splits on Pulminiq

Chiron's Pulminiq -- a treatment for preventing lung transplant rejection -- has received a split decision by an influential FDA advisory panel. The panel voted 8-8 on Pulminiq after staffers had questioned the accuracy of data drawn from a small clinical trial. The trial found a 79 percent reduction in the risk of death among the 26 patients using the drug. Some members of the panel wondered if other factors could have influenced the data. The drug is only a small one for Chiron, though, with an estimated market value of $40 million to $75 million. The FDA will now take up the issue and decide by July 14.

- read this article from the San Francisco Chronicle

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.